American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

Published on by Steven Cannady

Steven Cannady – Philadelphia, Pennsylvania

Practice Contact Information

University of Pennsylvania
800 Walnut Street
18th floor
Philadelphia
Pennsylvania
19107
United States

Phone: 215-829-5183
Email:
Web Site: https://www.pennmedicine.org/providers/profile/steven-cannady?fadf=PennCancer

Areas of surgical specialization in Head and Neck Surgery

Head and Neck Surgeon, Reconstructive Head & Neck Surgery

Biography/Statement

Since completion of medical school at Ohio State University, then residency in Otolaryngology at Cleveland Clinic and fellowship at Oregon Health Sciences University in my specialty, I’ve pursued the best possible clinical care for my patients.  Over this time, I have dedicated myself to comprehensive oncologic surgical options and reconstructive procedures to restore the form and function of patients undergoing head and neck surgery.  I have invested countless hours learning and attempting to improve my skill set with the singular intention of being able to offer state of the art restorative procedures after cancer in the critically important areas of the body for speech, appearance, and swallowing.  I have increased the number of patients offered complex reconstructive options within my department, and focused research efforts on innovative procedures, operative accuracy, and patient centered outcomes.  I have developed a patented surgical instrument useful in a cost conscious climate to standardize reconstructive results.  I have published on the design and implementation of a new reconstructive flap over the past year that has been accepted as a novel and clinically useful surgical procedure.

I participate actively in outreach programs for patients in the community and general and specialty specific providers across our region.  These efforts to lecture and educate the community on head and neck disorders have impacted care via earlier referrals and awareness on the part of community providers.  Within Otorhinolaryngology I have served as the Director of Microvascular Surgery and Education since 2015; the roles of the position are to coordinate the clinical care of patients requiring this type of reconstruction, mentor and recruit junior faculty, and educate our trainees in this field.   I was a part of co-founding the Philadelphia Head and Neck Cancer Society (PHNCS) over the past several years.  The organization meets regularly and has begun regional research collaboration efforts in its two years of existence, while providing regional trainees the opportunity to present and learn at quarterly events.

 

Clinical Trials

Please see weblink to practice

Bibliography

Please see weblink to practice

Published on by Joseph Golden

Blake Golden – Seattle, WA

Practice Contact Information

Swedish Cancer Institute
1221 Madison Street
Suite 1523
Seattle
WA
98104
United States

Phone: 2062926464
Email: blake.golden@swedish.org
Web Site: https://www.swedish.org/services/head-and-neck-surgery

Areas of surgical specialization in Head and Neck Surgery

Endocrine Surgery, Head and Neck Surgeon, Reconstructive Head & Neck Surgery

Biography/Statement

Dr. Golden is a board-certified and fellowship-trained Head and Neck Surgeon. He practices the full spectrum of Head and Neck Oncology, including Endocrine Surgery, Microvascular Reconstruction, and Robotic Surgery among others. After serving on active duty in the United States Army, he joined the Swedish Head and Neck Surgery practice in 2017. Dr. Golden focuses on treating the patient, not the disease. This means listening to the patient’s concerns, discussing diagnoses and treatment options in understandable terms, and making decisions with the patient, not for the patient. Dr. Golden is dedicated to offering state-of-the-art, cutting edge cancer care. In his free time, Dr. Golden enjoys running, surfing, hiking, and cooking.

Clinical Trials

Bibliography

Published on by Jeffson Chung

Jeffson Chung – MORGANTOWN, West Virginia

Practice Contact Information

WEST VIRGINIA UNIVERSITY
1 MEDICAL CENTER DRIVE
HSC SOUTH, RM 4500
MORGANTOWN
West Virginia
26506
United States

Phone:
Email:
Web Site:

Areas of surgical specialization in Head and Neck Surgery

Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon, Reconstructive Head & Neck Surgery

Biography/Statement

Jeffson Chung, MD received his medical degree from the School of Medicine at Queen’s University in Kingston, Ontario.  He completed a residency in otolaryngology – head and neck surgery at the University of Ottawa, and is certified by the Royal College of Physicians and Surgeons of Canada.  Dr. Chung then went on to the University of Alberta, where he completed a fellowship in advanced training in head and neck oncologic surgery sponsored by the American Head & Neck Society.

Dr. Chung specialized in head and neck cancers, transoral robotic surgery, thyroid and parathyroid disorders, and has expertise in microvascular free flap reconstructions.  He has research interests in survival and functional outcomes in cancer, the impact of technology on an otolaryngology practice, and the implementation of telemedicine in otolaryngology.

Clinical Trials

Bibliography

Published on by Phillip Pirgousis

Phil Pirgousis – Jacksonville, Florida

Practice Contact Information

Mayo Clinic- College of Medicine, Jacksonville, Florida
4500 San Pablo Road
FLA Davis Building, 3rd Floor
Jacksonville
Florida
32224
United States

Phone: 904-953-6674
Email: pirgousis.phillip@mayo.edu
Web Site:

Areas of surgical specialization in Head and Neck Surgery

Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon, Reconstructive Head & Neck Surgery

Biography/Statement

I am Associate Professor of Otorhinolaryngology/ Head & Neck Surgery at the Mayo Clinic, College of Medicine in Jacksonville, Florida.

My clinical and research interests include benign and malignant diseases of the Head & Neck area, including the skin and Skull Base region. In addition, my practice involves head and neck endocrine surgery as well as microvascular reconstructive surgery and rehabilitation for head and neck surgical defects with an emphasis on optimizing functional outcomes for patients.

Clinical Trials

Bibliography

Published on by Jeffrey Myers

Jeffrey Myers – Houston, Texas

Practice Contact Information

University of Texas MD Anderson Cancer Center
1515 West Holcombe Boulevard
Ste 1445
Houston
Texas
77030
United States

Phone: (713) 792 – 6920
Email:
Web Site: https://faculty.mdanderson.org/profiles/jeffrey_myers.html

Areas of surgical specialization in Head and Neck Surgery

Head and Neck Surgeon

Biography/Statement

Dr. Jeffrey N. Myers received his medical (MD) and doctoral (PhD) degrees from the University of Pennsylvania School of Medicine and he then completed his residency training in Otolaryngology-Head and Neck Surgery at the University of Pittsburgh. He subsequently completed fellowship training in Head and Neck Surgical Oncology at the University of Texas MD Anderson Cancer Center, where he has been on the faculty ever since. Dr. Myers leads a basic and translational research program and his primary research interests are in the role of p53 mutation in oral cancer progression, metastasis and response to treatment.

Clinical Trials

  1. Premalignant

Personalized, randomized, phase 2 study of pembrolizumab (MK-3475) for high risk oral intra-epithelial neoplasias

(IPOC)

 

Checkpoint Inhibitors (PD-L1/CTLA-4) Assessment in Oropharynx Carcinoma (CIAO)

III. Preoperative — High Risk

Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC Pembrolizumab  

  1. Postoperative — Intermediate Risk

RTOG-0920 1 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for locally advanced resected Head & Neck cancer

 — High Risk

RTOG-1216 1 Randomized Ph II/III Trial of Surgery and PORT Delivered with Concurrent Cisplatin Versus Docetaxel Versus Cetuximab and Docetaxel for High‐Risk SCCHN

 

A Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy versus Intensity-Modulated Photon

Therapy for the treatment of OPSCC

 

Observational Parallel Cohort Study of Intensity-Modulated Proton Therapy or TransOral Robotic Surgery for the

Treatment of Low-Risk OPSCC.

–

A Phase 1b Trial of LY2606368 (CHK1) in Combination with Chemoradiation in Patients with Locally Advanced

HNSCC

 

RTOG 3504 4 Randomized Ph 3 Trial of Cisplatin-Based CRT +/- Nivolumab in Patients with Intermediate and High-Risk

Local-Regionally Advanced HNSCC

 

Bayesian Phase II Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human

Papilloma Virus Positive Oropharyngeal Cancer

 

A Phase 3 Study of Nivolumab+/-Cisplatin, in combo w/ XRT in Participants with Cisplatin Ineligible and Eligible

Locally Advanced SCCHN

VII. Locoregional Recurrence

2016-0805 1 Checkpoint Inhibitors (PD-L1/CTLA-4) Assessment in Oropharynx Carcinoma (CIAO)

Durvalumab +/- Tremelimumab

Ph 2 Randomized Trial of Stereotactic Onco-Ablative Reirradiation vs Conventionally Fractionated Conformal XRT

for Patients with Small Inoperable HN Tumors (SOAR-HN)VIII

 

After completing my residency in Otolaryngology-Head and Neck Surgery at the University of Pittsburgh School of Medicine, I completed a year of fellowship training in Head and Neck Oncologic Surgery at the University of Texas MD Anderson Cancer Center in 1997.  I stayed on at MD Anderson Cancer Center since that time and in 2017, I became the Chair of the Department of Head and Neck Surgery.  My practice encompasses the spectrum of Head and Neck Oncologic Surgery and emphasizes multi-disciplinary care to obtain the best survival and quality of life outcomes for my patients. I have sub-specialty interests in caring for patients with cancers of the oral cavity (mouth) and skin. My practice philosophy is to care for others the way I would want my own family members to be cared for and to listen patients so that I can help them best achieve their personal goals for their treatment.. Metastatic/Recurrent Front-Line

Bibliography

 

  1. Kokai Y, Dobashi K, Weiner DB, Myers JN, Nowell PC, Greene MI. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. Proc Natl Acad Sci U S A 85(15):5389-93, 8/1988. PMID: 2899889.
  2. Williams WV, Guy HR, Rubin DH, Robey F, Myers JN, Kieber-Emmons T, Weiner DB, Greene MI. Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. Proc Natl Acad Sci U S A 85(17):6488-92, 9/1988. PMID: 2457914.
  3. Williams WV, Moss DA, Kieber-Emmons T, Cohen JA, Myers JN, Weiner DB, Greene MI. Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci U S A 86(14):5537-41, 7/1989. PMID: 2501789.
  4. Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58(2):287-92, 7/1989. PMID: 2568888.
  5. Wada T, Myers JN, Kokai Y, Brown VI, Hamuro J, LeVea CM, Greene MI. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene 5(4):489-95, 4/1990. PMID: 1970151.
  6. Mikami Y, Davis JG, Dobashi K, Dougall WC, Myers JN, Brown VI, Greene MI. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product. Proc Natl Acad Sci U S A 89(16):7335-9, 8/1992. PMID: 1354355.
  7. Myers JN, LeVea CM, Smith JE, Kallen RG, Tung L, Greene MI. Expression, purification, and characterization of Bacneu. A soluble protein tyrosine kinase domain encoded by the neu-oncogene. Receptor 2(1):1-16, 1992. PMID: 1362129.
  8. Weissman JL, Myers JN, Kapadia SB. Extramedullary plasmacytoma of the larynx. Am J Otolaryngol 14(2):128-31, 3/1993. PMID: 8484478.
  9. LeVea CM, Myers JN, Dougall WC, Qian X, Greene MI. A structural and kinetic comparison of proto-oncogenic and oncogenic neu holo-receptors expressed in insect cells. Receptor 3(4):293-309, 1993. PMID: 7908242.
  10. Myers JN, Peel RL, Myers EN. Pathologic quiz case 1. Malignant lymphoepithelial lesion of the parotid gland. Arch Otolaryngol Head Neck Surg 121(4):479-82, 4/1995. PMID: 7702826.
  11. Aydogan LB, Myers JN, Myers EN, Kirkwood J. Malignant melanoma metastatic to the tonsil. Laryngoscope 106(3 Pt 1):313-6, 3/1996. PMID: 8614195.
  12. Myers JN, Yasumura S, Suminami Y, Hirabayashi H, Lin W, Johnson JT, Lotze MT, Whiteside TL. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 2(1):127-35, 1996. PMID: 9816099.
  13. Myers JN, Mank-Seymour A, Zitvogel L, Storkus W, Clarke M, Johnson CS, Tahara H, Lotze MT. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope 108(2):261-8, 2/1998. PMID: 9473079.
  14. Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 124(6):641-6, 6/1998. PMID: 9639473.
  15. Beaver ME, Myers JN, Griffenberg L, Waugh K. Percutaneous fluoroscopic gastrostomy tube placement in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 124(10):1141-4, 10/1998. PMID: 9776193.
  16. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59(8):1820-4, 4/1999. PMID: 10213484.
  17. Jin YT, Myers JN, Tsai ST, Goepfert H, Batsakis JG, el-Naggar AK. Genetic alterations in oral squamous cell carcinoma of young adults. Oral Oncol 35(3):251-6, 5/1999. PMID: 10621844.

 

 

  1. El-Naggar AK, Lai S, Clayman GL, Zhou JH, Tucker SA, Myers JN, Luna MA, Benedict WF. Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol 30(9):1013-8, 9/1999. PMID: 10492034.
  2. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 125(10):1083-9, 10/1999. PMID: 10522499.
  3. Myers JN, Elkins T, Roberts D, Byers RM. Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol Head Neck Surg 122(1):44-51, 2000. PMID: 10629481.
  4. Esmaeli B, Medeiros LJ, Myers JN, Champlin R, Singh S, Ginsberg L. Orbital mass secondary to precursor T-cell acute lymphoblastic leukemia: a rare presentation. Arch Ophthalmol 119(3):443-6, 3/2001. PMID: 11231781.
  5. Spring PM, Myers JN, El-Naggar AK, Langstein HN. Malignant melanoma arising within a burn scar-case report and review of the literature. Ann Otol Rhinol Laryngol 110(4):369-76, 4/2001. PMID: 11307915.
  6. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers JN, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7(5):1204-13, 5/2001. PMID: 11350885.
  7. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers JN, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19(12):3010-7, 6/2001. PMID: 11408495.
  8. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92(9):2364-73, 11/2001. PMID: 11745292.
  9. Myers JN, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer 92(12):3030-6, 12/2001. PMID: 11753980.
  10. Beaver ME, Matheny KE, Roberts DB, Myers JN. Predictors of weight loss during radiation therapy. Otolaryngol Head Neck Surg 125(6):645-8, 12/2001. PMID: 11743469.
  11. Zinner RG, Nemunaitis JJ, Donato NJ, Shin HC, Myers JN, Zhang PS, Zentgraft RE, Lee JJ, Khuri FR, Glisson BS, Eiseman I, Olson SC, Bycott P, Lenehan PF, Hong WK, Shin DM. A phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033, in patients with solid tumors. Clin Cancer Res 7(11):566, 2001.
  12. Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, Yen SH, Lotze MT. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 60(2):110-5, 2001. PMID: 11244324.
  13. Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 8(1):293-8, 1/2002. PMID: 11801572.
  14. Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers JN, Goepfert H, Lotan R, Hong WK, Lipman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. Journal of Clinical Oncology 20(2):364-70, 1/2002.
  15. Eicher SA, Clayman GL, Myers JN, Gillenwater AM. A prospective study of intraoperative lymphatic mapping for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg 128(3):241-6, 3/2002. PMID: 11886337.
  16. Holsinger FC, Owens JM, Raymond AK, Myers JN. Central mucoepidermoid carcinoma of the mandible: tumorigenesis within a keratocyst. Arch Otolaryngol Head Neck Surg 128(6):718-20, 6/2002. PMID: 12049571.

 

 

  1. Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Jr, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers JN, Clayman G, Hong WK. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95(2):322-30, 7/2002. PMID: 12124833.
  2. Myers JN, Holsinger FC, Bekele BN, Li E, Jasser SA, Killion JJ, Fidler IJ. Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch Otolaryngol Head Neck Surg 128(8):875-9, 8/2002. PMID: 12162763.
  3. Lewin JS, Gillenwater AM, Garrett JD, Bishop-Leone JK, Nguyen DD, Callender DL, Ayers GD, Myers JN. Characterization of laryngopharyngeal reflux in patients with premalignant or early carcinomas of the larynx. Cancer 97(4):1010-4, 2/2003. PMID: 12569600.
  4. Greenberg JS, Fowler R, Gomez J, Mo V, Roberts D, El Naggar AK, Myers JN. Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer 97(6):1464-70, 3/2003. PMID: 12627511.
  5. Ballo MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, Schechter NR, Morrison WH, Ross MI, Kian Ang K. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 97(7):1789-96, 4/2003. PMID: 12655537.
  6. Werner JA, Dunne AA, Myers JN. Functional anatomy of the lymphatic drainage system of the upper aerodigestive tract and its role in metastasis of squamous cell carcinoma. Head Neck 25:322-32, 4/2003. PMID: 12658737.
  7. Greenberg JS, El Naggar AK, Mo V, Roberts D, Myers JN. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 98(3):508-15, 8/2003. PMID: 12879467.
  8. Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA, Bekele BN, Younes MN, Bucana CD, Fidler IJ, Myers JN. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 9:3183-9, 8/2003. PMID: 12912971.
  9. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 129:864-8, 8/2003. PMID: 12925346.
  10. Swan EA, Jasser SA, Holsinger FC, Doan D, Bucana C, Myers JN. Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol 39:648-55, 10/2003. PMID: 12907203.
  11. Bonnen MD, Ballo MT, Myers JN, Garden AS, Diaz EM, Jr, Gershenwald JE, Morrison WH, Lee JE, Oswald MJ, Ross MI, Ang KK. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 100(2):383-9, 1/2004. PMID: 14716775.
  12. Younes MN, Myers JN. Melanoma of the head and neck: Current concepts in staging, diagnosis, and management. Surg Oncol Clin N Am. 13:201-29, 1/2004.
  13. Garden AS, Asper JA, Morrison WH, Schechter NR, Glisson BS, Kies MS, Myers JN, Ang KK. Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma? Cancer 100(6):1171-8, 3/2004. PMID: 15022283.
  14. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 111:679-92, 9/2004. PMID: 15252836.
  15. Curino A, Patel V, Nielsen BS, Iskander AJ, Ensley JF, Yoo GH, Holsinger FC, Myers JN, El-Nagaar A, Kellman RM, Shillitoe EJ, Molinolo AA, Gutkind JS, Bugge TH. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. Oral Oncol 40:1026-32, 11/2004. PMID: 15509494.
  16. Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD, Bekele BN, Fidler IJ, Myers JN. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 64:7977-84, 11/2004. PMID: 15520205.
  17. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and

 

 

the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10:8594-602, 12/2004. PMID: 15623643.

  1. Esmaeli B, Ahmadi MA, Youssef A, Diba R, Amato M, Myers JN, Kies M, El-Naggar A. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg 20:22-6, 2004. PMID: 14752305.
  2. Prabhu SS, Diaz E, Sturgis EM, Myers JN, Suki D, DeMonte F. Section on tumors: Mahaley clinical research award: Primary sarcomas of the skull base: an analysis of 63 cases. Clin Neurosurg 51:340-2, 2004. PMID: 15571164.
  3. Yan C, Jamaluddin MS, Aggarwal B, Myers JN, Boyd DD. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 4:233-41, 2/2005. PMID: 15713895.
  4. Baker H, Patel V, Molinolo AA, Shillitoe EJ, Ensley JF, Yoo GH, Meneses-Garcia A, Myers JN, El-Naggar AK, Gutkind JS, Hancock WS. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol 41:183-99, 2/2005. PMID: 15695121.
  5. Park YW, Younes MN, Jasser SA, Yigitbasi OG, Zhou G, Bucana CD, Bekele BN, Myers JN. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 11:1963-73, 3/2005. PMID: 15756022.
  6. Kim S, Park YW, Schiff BA, Doan DD, Yazici Y, Jasser SA, Younes M, Mandal M, Bekele BN, Myers JN. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res 11:1713-21, 3/2005. PMID: 15755992.
  7. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, Mandal M, Myers JN. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 4:632-40, 4/2005. PMID: 15827337.
  8. Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92:1899-905, 5/2005. PMID: 15870708.
  9. Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, Yazici YD, Mandal M, Bekele BN, Bucana CD, Fidler IJ, Myers JN. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res 65:4716-27, 6/2005. PMID: 15930290.
  10. Maruya S, Kies MS, Williams M, Myers JN, Weber RS, Batsakis JG, El-Naggar AK. Differential expression of p63 isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications. Hum Pathol 36:821-7, 7/2005. PMID: 16084953.
  11. Maruya SI, Myers JN, Weber RS, Rosenthal DI, Lotan R, El-Naggar AK. ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion! Oral Oncol 41:580-8, 7/2005. PMID: 15975520.
  12. Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, Myers JN, Gibson SB, Murphy LC, Watson PH. The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res 65:5696-702, 7/2005. PMID: 15994944.
  13. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar A, Bekele BN, Mills GB, Myers JN. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 4:1146-56, 8/2005. PMID: 16093430.
  14. Ballo MT, Garden AS, Myers JN, Lee JE, Diaz EM, Jr, Sturgis EM, Morrison WH, Gershenwald JE, Ross MI, Weber RS, Ang KK. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck 27:718-21, 8/2005. PMID: 15952196.
  15. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyl transferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97:1272-86, 9/2005. PMID: 16145048.
  16. Schiff BA, Roberts DB, El-Naggar A, Garden AS, Myers JN. Selective vs modified radical neck dissection and postoperative radiotherapy vs observation in the treatment of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg 131:874-8, 10/2005. PMID: 16230589.

 

 

  1. Yao M, Roebuck JC, Holsinger FC, Myers JN. Elective neck dissection during salvage laryngectomy. Am J Otolaryngol 26:388-92, 11/2005. PMID: 16275407.
  2. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104(11):2430-6, 12/2005. PMID: 16245318.
  3. Yazici YD, Kim S, Jasser SA, Wang Z, Carter KB, Jr, Bucana CD, Myers JN. Antivascular therapy of oral tongue squamous cell carcinoma with PTK787. Laryngoscope 115:2249-55, 12/2005. PMID: 16369175.
  4. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, Myers JN. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 12(2):600-7, 1/2006. PMCID: PMC1403833.
  5. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 12:653-61, 1/2006. PMID: 16428512.
  6. Kupferman M, Myers JN. Molecular biology of oral cavity squamous cell carcinoma. Otolaryngol Clin North Am 39:229-47, 4/2006. PMID: 16580909.
  7. Simon C, Goepfert H, Rosenthal DI, Roberts D, El-Naggar A, Old M, Diaz EM, Jr, Myers JN. Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol 263:313-8, 4/2006. PMID: 16328403.
  8. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 119(6):1268-75, 4/2006. PMID: 16642480.
  9. Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphey A, Ludwick J, El-Naggar AK, Bucana C, Mills GB, Myers JN. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol 42(4):430-9, 4/2006. e-Pub 1/2006. PMCID: PMC1414640.
  10. Kim S, Yazici YD, Barber SE, Jasser SA, Mandal M, Bekele BN, Myers JN. Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11. Head Neck 28:389-99, 5/2006. PMID: 16388530.
  11. Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res 12:3425-34, 6/2006. PMID: 16740767.
  12. Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res 12:4755-65, 8/2006. PMID: 16899627.
  13. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers JN, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24:4163-9, 9/2006. PMID: 16943532.
  14. Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El-Naggar AK, Myers JN. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 5:2696-705, 11/2006. PMID: 17121916.
  15. Williams MD, Chakravarti N, Kies MS, Maruya S, Myers JN, Haviland JC, Weber RS, Lotan R, El-Naggar AK. Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 12:7353-8, 12/2006. PMID: 17189407.
  16. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GK. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 64:106-13, 2006. PMID: 16182463.

 

 

  1. Temam S, Janot F, Germain M, Julieron M, Bretagne E, Myers JN, Marandas P, Mamelle G, Leridant AM, Kolb F, Luboinski B. Functional results with advanced hypopharyngeal carcinoma treated with circular near-total pharyngolaryngectomy and jejunal free-flap repair. Head Neck 28:8-14, 2006. PMID: 16155913.
  2. Younes MN, Yigitbasi OG, Yazici YD, Jasser SA, Bucana CD, El-Naggar AK, Mills GB, Myers JN. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 133(1):15-23, 1/2007. PMID: 17224516.
  3. Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lin XL, Darnay BG, Chaturvedi MM, Aggarwal BB. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 26(10):1385-97, 3/2007. e-Pub 9/2006. PMID: 16953224.
  4. Prichard CN, Kim S, Yazici YD, Doan DD, Jasser SA, Mandal M, Myers JN. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 117(4):674-9, 4/2007. PMID: 17429874.
  5. Kupferman ME, Patel V, Sriuranpong V, Amornphimoltham P, Jasser SA, Mandal M, Zhou G, Wang J, Coombes K, Multani A, Pathak S, Silvio Gutkind J, Myers JN. Molecular analysis of anoikis resistance in oral cavity squamous cell carcinoma. Oral Oncol 43(5):440-54, 5/2007. e-Pub 9/2006. PMID: 16978912.
  6. Takeda I, Maruya S, Shirasaki T, Mizukami H, Takahata T, Myers JN, Kakehata S, Yagihashi S, Shinkawa H. Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci 98(6):890-9, 6/2007. e-Pub 4/2007. PMID: 17428261.
  7. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6(6):1785-92, 6/2007. PMID: 17575107.
  8. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, Kim KW, Hong WK, Lee HY. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99:949-61, 6/2007. e-Pub 6/2007. PMID: 17565155.
  9. Ren X, Xu Z, Myers JN, Wu X. Bypass NFkappaB-mediated survival pathways by TRAIL ans Smac. Cancer Biol Ther 7(6):1023-27, 7/2007.
  10. Gomez-Rivera F, Santillan-Gomez AA, Younes MN, Kim S, Fooshee D, Zhao M, Jasser SA, Myers JN. A tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res 1(13 (15Pt 1)):4519-27, 8/2007. PMID: 17671138.
  11. Melancon MP, Wang Y, Wen X, Bankson JA, Stephens LC, Jasser S, Gelovani JG, Myers JN, Li C. Developing of a macromolecular dual-modality MR-optical imaging for sentinel lymph node mapping. Investigative Radiology 42(8), 8/2007. PMCID: PMC2746745.
  12. Lee TK, Poon RT, Man K, Guan XY, Ma S, Liu XB, Myers JN, Yuen AP. Fascin over-expression is associated with aggressiveness of oral squamous cell carcinoma. Cancer Lett 254(2):308-15, 9/2007. e-Pub 5/2007. PMID: 17499430.
  13. Lee TK, Poon RT, Wo JY, Ma S, Guan XY, Myers JN, Altevogt P, Yuen AP. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res 67(18):8800-9, 9/2007.
  14. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: Implications for therapy. J Dent Res 87(1):14-32, 1/2008. PMID: 18096889.
  15. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93(1):278-84, 1/2008. e-Pub 11/2007. PMID: 17989125.
  16. Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE, El-Naggar AK. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-

 

 

regulation, vimentin expression, and aggressive tumor features. Cancer 112(9):2088-100, 5/2008. PMID: 18327819.

  1. Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, Ferlito A. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 30(6):800-9, 6/2008. PMID: 18429007.
  2. Kadara H, Tahara E, Kim HJ, Lotan D, Myers J, Lotan R. Involvement of Rac in fenretinide-induced apoptosis. Cancer Res 68(11):4416-23, 6/2008. PMID: 18519704.
  3. Zhou G, Xie TX, Zhao M, Jasser SA, Younes MN, Sano D, Lin J, Kupferman ME, Santillan AA, Patel V, Gutkind JS, El-Naggar AK, Emberley ED, Watson PH, Matsuzawa SI, Reed JC, Myers JN. Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene 27(25):3527-38, 6/2008. e-Pub 1/2008. PMID: 18223693.
  4. Choi S, Sano D, Cheung M, Zhao M, Jasser SA, Ryan AJ, Mao L, Chen WT, El-Naggar AK, Myers JN. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 14(16):5081-9, 8/2008. PMID: 18698025.
  5. Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, Al-Nuaim A, Al-Sobhi S, Al-Dayel F, Bavi P, Hussain AR, Al-Kuraya KS. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab 93(10):4088-97, 10/2008. e-Pub 8/2008. PMID: 18682509.
  6. Hleb EY, Hafner JH, Myers JN, Hanna EY, Rostro BC, Zhdanok SA, Lapotko DO. LANTCET: Elimination of solid tumor cells with photothermal bubbles generated around clusters of gold nanoparticles. Nanomedicine (Lond) 3(5):647-67, 10/2008. PMID: 18817468.
  7. Gomez-Rivera F, Santillan A, McMurphey AB, Paraskevopoulos G, Roberts DB, Prieto VG, Myers JN. Sentinel node biopsy in patients with cutaneous melanoma of the head and neck: recurrence and survival study. Head Neck 30(10):1284-94, 10/2008. e-Pub 8/2008. PMID: 18704971.
  8. Gelbard A, Kupferman ME, Jasser SA, Chen W, El-Naggar AK, Myers JN, Hanna EY. An orthotopic murine model of sinonasal malignancy. Clin Cancer Res 14(22):7348-57, 11/2008. PMID: 19010850.
  9. Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 30(12):1592-98, 12/2008. PMID: 18798304.
  10. Chakravarty G, Santillan AA, Galer C, Adams HP, El-Naggar AK, Jasser SA, Mohsin S, Mondal D, Clayman GL, Myers JN. Phosphorylated insulin like growth factor-I receptor expression and it’s clinico-pathological significance in histologic subtypes of human thyroid cancer. Exp Biol Med (Maywood) 234(4):372-86, 4/2009. e-Pub 1/2009. PMID: 19176870.
  11. Sano D, Choi S, Milas ZL, Zhou G, Galer CE, Su YW, Gule M, Zhao M, Zhu Z, Myers JN. The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg 135(4):411-20, 4/2009. e-Pub 2009. PMCID: PMC2914603.
  12. Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol 27(28):4727-32, 10/2009. e-Pub 8/2009. PMCID: PMC2754914.
  13. Kupferman ME, Jayakumar A, Zhou G, Xie T, Dakak-Yazici Y, Zhao M, Ju J, Mandal M, Jasser S, Madden T, Myers JN, Priebe W. Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 8(2):117-27, 2009. PMID: 20192118.
  14. Sano D, Myers JN. Xenograft models of head and neck cancers. Head Neck Oncol 1(1):32, 2009. e-Pub 8/2009. PMCID: PMC2737672.
  15. Wang LE, Hu Z, Sturgis EM, Spitz MR, Strom SS, Amos CI, Guo Z, Qiao Y, Gillenwater AM, Myers JN, Clayman GL, Weber RS, El-Naggar AK, Mao L, Lippman SM, Hong WK, Wei Q. Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts

 

 

contributes to risk of head and neck cancer but not tumor characteristics. Clin Cancer Res 16(2):764-74, 1/2010. e-Pub 1/2010. PMCID: PMC2848391.

  1. Chakravarti N, Kadara H, Yoon DJ, Shay JW, Myers JN, Lotan D, Sonenberg N, Lotan R. Differential inhibition of protein translation machinery by curcumin in normal, immortalized and malignant oral epithelial cells. Cancer Prev Res (Phila) 3(3):331-8, 3/2010. e-Pub 2/2010. PMCID: PMC2833226.
  2. Mittal MK, Myers JN, Bailey CK, Misra S, Chaudhuri G. Mode of action of the retrogene product SNAI1P, a SNAIL homolog, in human breast cancer cells. Mol Biol Rep 37(3):1221-7, 3/2010. e-Pub 3/2009. PMCID: PMC2824646.
  3. Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, Petruzelli G, Gourin CG, Wong RJ, Ferris RL, El Naggar A, Ridge JA, Paniello RC, Owzar K, McCall L, Chepeha DB, Yarbrough WG, Myers JN. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: Results of a prospective multi-institutional trial. J Clin Oncol 28(8):1395-400, 3/2010. e-Pub 2/2010. PMCID: PMC2834497.
  4. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16(6):1834-44, 3/2010. e-Pub 3/2010. PMCID: PMC2858983.
  5. Behren A, Kamenisch Y, Muehlen S, Flechtenmacher C, Haberkorn U, Hilber H, Myers JN, Bergmann Z, Plinkert PK, Simon C. Development of an oral cancer recurrence mouse model after surgical resection. Int J Oncol 36(4):849-55, 4/2010. PMID: 20198328.
  6. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN. TrkB induces EMT and plays a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29(14):2047-59, April, 4/2010. e-Pub 1/2010. PMCID: PMC3138334.
  7. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/FAR/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116(12):2974-83, 6/2010. PMID: 20564403.
  8. Guadagnolo BA, Myers JN, Zagars GK. Role of postoperative irradiation for patients with bilateral cervical nodal metastases from cutaneous melanoma: A critical assessment. Head Neck 32(6):708-13, 6/2010. e-Pub 9/2009. PMID: 19787786.
  9. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 6/2010. e-Pub 6/2010. PMCID: PMC2913168.
  10. Berlin JM, Leonard AD, Pham TT, Sano D, Marcano DC, Yan S, Fiorentino S, Milas ZL, Kosynkin DV, Price BK, Lucente-Schultz RM, Wen X, Raso MG, Craig SL, Tran HT, Myers JN, Tour JM. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified Paclitaxel. ACS Nano 4(8):4621-36, 8/2010. PMCID: PMC2935702.
  11. Yilmaz T, Jiffar T, de la Garza G, Lin H, Milas Z, Takahashi Y, Hanna E, MacIntyre T, Brown JL, Myers JN, Kupferman ME. Therapeutic targeting of Trk suppresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol Ther 10(6):644-53, 9/2010. e-Pub 9/2010. PMCID: PMC3230305.
  12. Wang J, Byers LA, Yordy JS, Liu W, Shen L, Baggerly KA, Giri U, Myers JN, Ang KK, Story MD, Girard L, Minna JD, Heymach JV, Coombes KR. Blasted cell line names. Cancer Inform 9:251-5, 2010. e-Pub 10/2010. PMCID: PMC2978931.
  13. Savar A, Oellers P, Myers J, Prieto VG, Torres-Cabala C, Frank SJ, Ivan D, Esmaeli B. Positive sentinel node in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg 27(1):e4-6, Jan-Feb, 1/2011. PMID: 20940661.
  14. Galer CE, Corey CL, Wang Z, Younes MN, Gomez-Rivera F, Jasser SA, Ludwig DL, El-Naggar AK, Weber RS, Myers JN. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: Reduction of angiogenesis and tumor growth in

 

 

cutaneous squamous cell carcinoma. Head Neck 33(2):189-98, 2/2011. e-Pub 5/2010. PMCID: PMC3010504.

  1. Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF 3rd, Calvert VS, Fodale V, Wang J, Weber RS. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178(2):548-71, 2/2011. PMCID: PMC3070553.
  2. Ow TJ, Myers JN. Current management of advanced resectable oral cavity squamous cell carcinoma. Clin Exp Otorhinolaryngol 4(1):1-10, 3/2011. e-Pub 3/2011. PMCID: PMC3062220.
  3. Sano D, Fooshee DR, Zhao M, Andrews GA, Frederick MJ, Galer C, Milas ZL, Morrow PK, Myers JN. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head Neck 33(3):349-58, 3/2011. PMCID: PMC2958241.
  4. Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT detecting thyroid plasmacytoma after the successful treatment of gastric large B-cell lymphoma. Clinical Nuclear Medicine 36(4):317-9, 4/2011. PMID: 21368613.
  5. Su Ying-Wen, Xie Tong-xie, Sano D, Myers JN. IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2. PLos One 6(4), 4/2011. PMCID: PMC3084854.
  6. Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res 21(2):127-30, 4/2011. PMID: 21169870.
  7. Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, Schwartz DL, Bankson JA, Myers JN, Lai SY. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 17(8):2281-91, 4/2011. e-Pub 1/2011. PMCID: PMC3079006.
  8. Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN. Vandetanib restores head and neck squamous cell carcinoma cells’ sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 17(7):1815-27, 4/2011. e-Pub 2/2011. PMCID: PMC3074405.
  9. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117(13):2926-38, 7/2011. e-Pub 1/2011. PMCID: PMC3135768.
  10. Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, Yu D, Myers JN, Kupferman ME. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene 30(28):3163-73, 7/2011. PMCID: PMC3136629.
  11. Berlin JM, Pham TT, Sano D, Mohamedali KA, Marcano DC, Myers JN, Tour JM. Noncovalent functionalization of carbon nanovectors with an antibody enables targeted drug delivery. ACS Nano 5(8):6643-50, 8/2011. e-Pub 7/2011. PMCID: PMC3160510.
  12. Yom SS, Garden AS, Staerkel GA, Ginsberg LE, Morrison WH, Sturgis EM, Rosenthal DI, Myers JN, Edeiken-Monroe BS. Sonographic examination of the neck after definitive radiotherapy for node-positive oropharyngeal cancer. AJNR Am J Neuroradiol 32(8):1532-8, 9/2011. e-Pub 7/2011. PMID: 21757532.
  13. Melancon MP, Lu W, Zhong M, Zhou M, Liang G, Elliott AM, Hazle JD, Myers JN, Li C, Stafford RJ. Targeted multifunctional gold-based nanoshells for magnetic resonance-guided laser ablation of head and neck cancer. Biomaterials 32(30):7600-8, 10/2011. e-Pub 7/2011. PMCID: PMC3195359.
  14. Liu Z, Wei S, Ma H, Zhao M, Myers JN, Weber RS, Sturgis EM, Wei Q. A functional variant at the miR-184 Binding Site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 32(11):1668-74, 11/2011. e-Pub 9/2011. PMCID: PMC3204352.
  15. Sano D, Xie TX, Ow TJ, Zhao M, Pickering CR, Zhou G, Sandulache VC, Wheeler DA, Gibbs RA, Caulin C, Myers JN. Disruptive TP53 mutation is associated with aggressive disease

 

 

characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res 17(21):6658-70, 11/2011. e-Pub 9/2011. PMCID: PMC3207013.

  1. Galer CE, Sano D, Ghosh SC, Hah JH, Auzenne E, Hamir AN, Myers JN, Klostergaard J. Hyaluronic acid-paxlitaxel conjugate inhibits growth of human squamous cell carcinoma of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol 47(11):1039-47, 11/2011. e-Pub 9/2011. PMID: 21903450.
  2. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN. Assembly and initial characterization of a panel of 85 genomically validated cells lines from diverse head and neck tumor sites. Clin Cancer Res 17(23):7248-64, 12/2011. e-Pub 8/2011. PMCID: PMC3229662.
  3. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C. Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidrasky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzer KW, Myers JN. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046):1154-7, 2011. e-Pub 7/2011. PMCID: PMC3162986.
  4. Wang Y, Ow TJ, Myers JN. Pathways for cervical metastasis in malignant neoplasms of the head and neck region. Clin Anat 25(1):54-71, 1/2012. e-Pub 8/2011. PMID: 21853469.
  5. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 18(1):290-300, 1/2012. e-Pub 11/2011. PMCID: PMC3251726.
  6. Sandulache VC, Myers JN. Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets. Head Neck 34(2):282-90, 2/2012. e-Pub 2/2011. PMCID: PMC3839242.
  7. Sandulache VC, Skinner HD, Ow TJ, Zhang A, Xia X, Luchak JM, Wong LJ, Pickering CR, Zhou G, Myers JN. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer 118(3):711-21, 2/2012. e-Pub 6/2011. PMCID: PMC3188683.
  8. Sano D, Berlin JM, Pham TT, Marcano DC, Valdecanas DR, Zhou G, Milas L, Myers JN, Tour JM. Non-Covalent Assembly of Targeted Carbon Nanovectors Enables Synergistic Drug and Radiation Cancer Therapy In Vivo. ACS Nano 6(3):2497-505, 3/2012. PMCID: PMC3314092.
  9. Thariat J, Ang KK, Allen PK, Ahamad A, Williams MD, Myers JN, El-Naggar AK, Ginsberg LE, Rosenthal DI, Glisson BS, Morrison WH, Weber RS, Garden AS. Prediction of Neck Dissection Requirement After Definitive Radiotherapy for Head-and-Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 82(3):e367-74, 3/2012. PMCID: PMC4124997.
  10. Sandulache VC, Skinner HD, Wang Y, Chen Y, Dodge CT, Ow TJ, Bankson JA, Myers JN, Lai SY. Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation. Mol Cancer Ther 11(6):1373-80, 6/2012. e-Pub 5/2012. PMCID: PMC3856684.
  11. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O’Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-1009. e-Pub 9/2012. PMID: 22950385.
  12. Takahashi Y, Kupferman ME, Bell D, Jiffar T, Lee JG, Xie T, Li NW, Zhao M, Frederick MJ, Gelbard A, Myers JN, Hanna EY. Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma. Clin Cancer Res 18(22):6178-87, 11/2012. PMCID: PMC3513379.
  13. El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli B. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol 130(12):1608-11, 12/2012. PMID: 23229707.

 

 

  1. Christensen JM, Baumann DP, Myers JN, Buretta K, Sacks JM. Indocyanine green near-infrared laser angiography predicts timing for the division of a forehead flap. Eplasty 12:e41, 2012. e-Pub 8/2012. PMCID: PMC3432576.
  2. Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, Zhong LP. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: A meta-analysis. Oral Oncol 48(11):1076-84, 2012. e-Pub 7/2012. PMID: 22800881.
  3. Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma. J Clin Oncol 31(6):744-51, 2/2013. e-Pub 11/2012. PMID: 23129742.
  4. Pickering CR, Myers JN. Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients. Cancer Discov 3(3):258-9, 3/2013. PMID: 23475877.
  5. Sano D, Gule MK, Rosenthal DI, Bell D, Yates J, El-Naggar AK, Myers JN. Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head Neck 35(3):321-8, 3/2013. e-Pub 2/2012. PMCID: PMC3836367.
  6. Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, Agrawal N. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck 35(3):454-63, 3/2013. e-Pub 8/2012. PMCID: PMC3715072.
  7. Zhong LP, Zhu DW, William WN, Liu Y, Ma J, Yang CZ, Yang X, Wang LZ, Li J, Myers JN, Lee JJ, Zhang CP, Zhang ZY. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther 12(6):1112-21, 6/2013. e-Pub 3/2013. PMID: 23515614.
  8. Xie TX, Zhou G, Zhao M, Sano D, Jasser SA, Brennan RG, Myers JN. Serine Substitution of Proline at Codon 151 of TP53 Confers Gain of Function Activity Leading to Anoikis Resistance and Tumor Progression of Head and Neck Cancer Cells. Laryngoscope 123(6):1416-23, 6/2013. e-Pub 4/2013. PMCID: PMC3664100.
  9. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, Weinstein JN, Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3(7):770-81, 7/2013. e-Pub 4/2013. PMCID: PMC3858325.
  10. Myers JN, Sturgis EM. A tale of two cancers: carcinomas of the oral cavity and oropharynx. Otolaryngol Clin North Am 46(4):xiii-xvi, 8/2013. e-Pub 5/2013. PMID: 23910479.
  11. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 119(16):3034-42, 8/2013. e-Pub 5/2013. PMCID: PMC3735618.
  12. Hamilton JD, Ahmed S, Sandulache VC, Daram SP, Ow TJ, Skinner HD, Rao A, Ginsberg LE, Kumar AJ, Myers JN. Improving Imaging Diagnosis of Persistent Nodal Metastases after Definitive Therapy for Oropharyngeal Carcinoma: Specific Signs for CT and Best Performance of Combined Criteria. AJNR Am J Neuroradiol 34(8):1637-1642, 8/2013. e-Pub 3/2013. PMCID: PMC3939678.
  13. Gyanchandani R, Sano D, Ortega Alves MV, Klein JD, Knapick BA, Oh S, Myers JN, Kim S. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol 49(8):761-70, 8/2013. e-Pub 4/2013. PMID: 23623402.
  14. Tan M, Myers JN, Agrawal N. Oral cavity and oropharyngeal squamous cell carcinoma genomics. Otolaryngol Clin North Am 46(4):545-66, 8/2013. e-Pub 6/2013. PMCID: PMC3734385.

 

 

  1. Pfeiffer ML, Yin VT, Myers J, Esmaeli B. Regional Nodal Recurrence of Sebaceous Carcinoma of the Caruncle 11 Years After Primary Tumor Resection. JAMA Ophthalmol 131(8):1-2, 8/2013. e-Pub 6/2013. PMID: 23765335.
  2. Gadhikar MA, Sciuto MR, Ortega Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 12(9):1860-73, 9/2013. PMCID: PMC3955083.
  3. Wu X, Bhayani MK, Dodge CT, Nicoloso MS, Chen Y, Yan X, Adachi M, Thomas L, Galer CE, Jiffar T, Pickering CR, Kupferman ME, Myers JN, Calin GA, Lai SY. Coordinated Targeting of the EGFR Signaling Axis by MicroRNA-27a*. Oncotarget 4(9):1388-98, 9/2013. e-Pub 8/2013. PMCID: PMC3824521.
  4. Sandulache VC, Ow TJ, Daram SP, Hamilton J, Skinner H, Bell D, Rosenthal DI, Beadle BM, Ang KK, Kies MS, Johnson FM, El-Naggar AK, Myers JN. Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck 35(10):1454-60, 10/2013. e-Pub 9/2012. PMID: 23018868.
  5. Ow TJ, Sandulache VC, Skinner HD, Myers JN. Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers. Cancer 119(22):3914-28, 11/2013. e-Pub 8/2013. PMCID: PMC3930628.
  6. El-Sawy T, Frank SJ, Hanna E, Sniegowski M, Lai SY, Nasser QJ, Myers J, Esmaeli B. Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas. Ophthal Plast Reconstr Surg 29(6):454-7, Nov-Dec, 11/2013. PMCID: PMC3830646.
  7. Gyanchandani R, Ortega Alves MV, Myers JN, Kim S. A Proangiogenic Signature is Revealed in FGF-Mediated Bevacizumab Resistant Head and Neck Squamous Cell Carcinoma. Mol Cancer Res 11(12):1585-96, 12/2013. e-Pub 10/2013. PMCID: PMC3955724.
  8. Monroe MM, Myers JN, Kupferman ME. Undertreatment of Thick Head and Neck Melanomas: An Age-based Analysis. Ann Surg Oncol 20(13):4362-9, 12/2013. e-Pub 8/2013. PMID: 23975303.
  9. Ali A, Wang Z, Fu J, Ji L, Liu J, Li L, Wang H, Chen J, Caulin C, Myers JN, Zhang P, Xiao J, Zhang B, Li X. Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells. Nat Commun 4:2667, 2013. PMCID: PMC3876931.
  10. Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Lai SY, Woolfson A, Lorenzi MV, Bell D, Williams MD, Johnson FM. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med 11(1):198, 2013. e-Pub 8/2013. PMCID: PMC3844397.
  11. Yang CZ, Ma J, Luo QQ, Neskey DM, Zhu DW, Liu Y, Myers JN, Zhang CP, Zhang ZY, Zhong LP. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma. J Oral Pathol Med 43(1):28-34, 1/2014. e-Pub 5/2013. PMID: 23710769.
  12. Zhou JH, Kim KB, Myers JN, Fox PS, Ning J, Bassett RL, Hasanein H, Prieto VG. Immunohistochemical Expression of Hormone Receptors in Melanoma of Pregnant Women, Nonpregnant Women, and Men. Am J Dermatopathol 36(1):74-9, 1/2014. e-Pub 6/2013. PMCID: PMC3795893.
  13. Gelbard A, Hale KS, Takahashi Y, Davies M, Kupferman ME, El-Naggar AK, Myers JN, Hanna EY. Molecular profiling of sinonasal undifferentiated carcinoma. Head Neck 36(1):15-21, 1/2014. e-Pub 4/2013. PMCID: PMC3874284.
  14. Melancon MP, Zhou M, Zhang R, Xiong C, Allen P, Wen X, Huang Q, Wallace M, Myers JN, Stafford RJ, Liang D, Ellington AD, Li C. Selective Uptake and Imaging of Aptamer- and Antibody-Conjugated Hollow Nanospheres Targeted to Epidermal Growth Factor Receptors Overexpressed in Head and Neck Cancer. ACS Nano 8(5):4530-4538, 5/2014. e-Pub 4/2014. PMCID: PMC4046795.

 

  1. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA, Skinner HD, Fitzgerald AL, Osman AA, Wei Y, Xia X, Songyang Z, Mills GB, Hung MC, Caulin C, Liang J, Myers JN. Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. Mol Cell 54(6):p960–974, 6/2014. e-Pub 5/2014. PMCID: PMC4067806.
  2. Shiwarski DJ, Shao C, Bill A, Kim J, Xiao D, Bertrand C, Seethala RR, Sano D, Myers JN, Ha PK, Grandis JR, Gaither LA, Puthenveedu MA, Duvvuri U. To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN. Clin Cancer Res 20(17). e-Pub 6/2014. PMCID: PMC4160843.
  3. Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, Sidransky D. Key tumor suppressor genes inactivated by “greater promoter” methylation and somatic mutations in head and neck cancer. Epigenetics 9(7):1031-46, 7/2014. e-Pub 5/2014. PMCID: PMC4143405.
  4. Sandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Metformin use is associated with improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 36(7):1039-43, 7/2014. e-Pub 1/2014. PMID: 23784886.
  5. Zhou G, Myers JN. Mutant p53 exerts oncogenic functions by modulating cancer cell metabolism. Mol Cell Oncol 1(3):e963441, Jul-Sep, 7/2014. e-Pub 12/2014. PMCID: PMC4904903.
  6. Pickering CR, Zhang J, Neskey DM, Zhao M, Jasser SA, Wang J, Ward A, Tsai CJ, Ortega Alves MV, Zhou JH, Drummond J, El-Naggar AK, Gibbs R, Weinstein JN, Wheeler DA, Wang J, Frederick MJ, Myers JN. Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin Cancer Res 20(14):3842-8, 7/2014. e-Pub 5/2014. PMCID: PMC4102633.
  7. Takahashi Y, Bell D, Agarwal G, Roberts D, Xie TX, El-Naggar A, Myers JN, Hanna EY. Comprehensive assessment of prognostic markers for sinonasal squamous cell carcinoma. Head Neck 36(8):1094-102, 8/2014. e-Pub 10/2013. PMID: 23836481.
  8. Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K. Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol 32(23):2486-95, 8/2014. e-Pub 7/2014. PMCID: PMC4121506.
  9. Hauff SJ, Raju SC, Orosco RK, Gross AM, Diaz-Perez JA, Savariar E, Nashi N, Hasselman J, Whitney M, Myers JN, Lippman SM, Tsien RY, Ideker T, Nguyen QT. Matrix-Metalloproteinases in Head and Neck Carcinoma-Cancer Genome Atlas Analysis and Fluorescence Imaging in Mice. Otolaryngol Head Neck Surg 151(4):612-8, 10/2014. e-Pub 8/2014. PMCID: PMC4469264.
  10. Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. e-Pub 10/2014. PMCID: PMC4414661.
  11. Luke GP, Myers JN, Emelianov SY, Sokolov KV. Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors. Cancer Res 74(19):5397-408, 10/2014. e-Pub 8/2014. PMCID: PMC4198334.
  12. Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther 13(11):2738-50, 11/2014. e-Pub 9/2014. PMCID: PMC4221385.
  13. Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck 36(11):1547-54, 11/2014. e-Pub 3/2014. PMCID: PMC4010580.

 

  1. Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Doddapaneni H, Shinbrot E, Covington KR, Zhang J, Seth S, Caulin C, Clayman GL, El-Naggar AK, Gibbs RA, Weber RS, Myers JN, Wheeler DA, Frederick MJ. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20(24):6582-92, 12/2014. e-Pub 10/2014. PMCID: PMC4367811.
  2. Klein JD, Sano D, Sen M, Myers JN, Grandis JR, Kim S. STAT3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma. PLoS One 9(1):e81819, 2014. e-Pub 1/2014. PMCID: PMC3880270.
  3. Chuang HC, Yang LP, Fitzgerald AL, Osman A, Woo SH, Myers JN, Skinner HD. The p53-Reactivating Small Molecule RITA Induces Senescence in Head and Neck Cancer Cells. PLoS One 9(8):e104821, 2014. e-Pub 8/2014. PMCID: PMC4132078.
  4. Hayes DN and the TCGA Hrad and Network, Myers JN. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature:576-82. e-Pub 1/2015. PMCID: PMCPMC4311405.
  5. Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN. Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High Risk TP53 Mutations in Head and Neck Cancer through Mito tic Arrest Followed by Senescence. Mol Cancer Ther 14(2):608-19, 2/2015. e-Pub 12/2014. PMCID: PMC4557970.
  6. Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN. Evolutionary Action Score of TP53 Coding Variants (EAp53) is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res 75(7):1205-15, 4/2015. e-Pub 2/2015. PMCID: PMC4615655.
  7. Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, Hsu TK, Pickering CR, Ward A, Patel A, Yordy JS, Skinner HD, Giri U, Sano D, Story MD, Beadle BM, El-Naggar AK, Kies MS, William WN, Caulin C, Frederick M, Kimmel M, Myers JN, Lichtarge O. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res 75(7):1527-36, 4/2015. e-Pub 1/2015. PMCID: PMC4383697.
  8. Woo SH, Yang LP, Chuang HC, Fitzgerald A, Lee HY, Pickering C, Myers JN, Skinner HD. Down-regulation of malic enzyme 1 & 2 sensitizes head and neck squamous cell carcinoma cells to therapy-induced senescence. Head Neck. e-Pub 5/2015. PMID: 25994759.
  9. Zhou JH, Sahin AA, Myers JN. Biobanking in Genomic Medicine. Arch Pathol Lab Med 139(6):812-8, 6/2015. PMCID: PMC4852858.
  10. Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med 7(293):293ra104, 6/2015. PMCID: PMC4587492.
  11. Davis-Malesevich MV, Goepfert R, Kubik M, Roberts DB, Myers JN, Kupferman ME. Recurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy. Head Neck 37(8):1116-21, 8/2015. e-Pub 7/2014. PMID: 24764188.
  12. Mazumdar T, Sen B, Wang Y, Peng S, Nicholas C, Glisson BS, Myers JN, Johnson FM. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anticancer Drugs 26(8):835-42, 9/2015. e-Pub 6/2015. PMCID: PMC4515205.
  13. Monroe MM, Pattisapu P, Myers JN, Kupferman ME. Sentinel Lymph Node Biopsy Provides Prognostic Value in Thick Head and Neck Melanoma. Otolaryngol Head Neck Surg 153(3):372-8, 9/2015. e-Pub 6/2015. PMID: 26070510.
  14. Chinn SB, Myers JN. Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions. J Clin Oncol 33(29):3269-76, 10/2015. e-Pub 9/2015. PMID: 26351335.

 

 

  1. William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol:1-8. e-Pub 11/2015. PMID: 26540028.
  2. Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila) 8(11):1027-35, 11/2015. e-Pub 9/2015. PMCID: PMC4777304.
  3. Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN, Osman AA. Wee-1 kinase inhibition sensitizes high risk HPV+ HNSCC to apoptosis accompanied by downregulation of MCl-1 and XIAP antiapoptotic proteins. Clin Cancer Res 21(21):4831-44, 11/2015. e-Pub 6/2015. PMCID: PMC4631620.
  4. Sandulache VC, Chen Y, Skinner HD, Lu T, Feng L, Court LE, Myers JN, Meyn RE, Fuller CD, Bankson JA, Lai SY. Acute tumor lactate perturbations as a biomarker of genotoxic stress: development of a biochemical model. Mol Cancer Ther 14(12):2901-8, 12/2015. e-Pub 9/2015. PMID: 26376962.
  5. Fitzgerald AL, Osman AA, Xie TX, Patel A, Skinner H, Sandulache V, Myers JN. Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells. Cell Death Dis 6:e1678, 2015. e-Pub 3/2015. PMCID: PMC4385922.
  6. Takahashi Y, Lee J, Pickering C, Bell D, Jiffar TW, Myers JN, Hanna EY, Kupferman ME. Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma. Head Neck. e-Pub 1/2016. PMID: 26752332.
  7. Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV negative head and neck cancer. Clin Cancer Res. e-Pub 4/2016. PMID: 27036135.
  8. Li Z, Gonzalez CL, Wang B, Zhang Y, Mejia O, Katsonis P, Lichtarge O, Myers JN, El-Naggar AK, Caulin C. Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53(R172H). J Pathol. e-Pub 7/2016. PMID: 27447534.
  9. Saluja K, Rao PH, Myers JN, El-Naggar AK. Novel t(1;3)(q21,p21) translocation in a basal cell adenocarcinoma of the parotid gland: potential association with tumorigenesis. Hum Pathol 54:189-92, 8/2016. e-Pub 4/2016. PMID: 27085552.
  10. Ma N, Jiang YW, Zhang X, Wu H, Myers JN, Liu P, Jin H, Gu N, He N, Wu FG, Chen Z. Enhanced Radiosensitization of Gold Nanospikes via Hyperthermia in Combined Cancer Radiation and Photothermal Therapy. ACS Appl Mater Interfaces. e-Pub 10/2016. PMID: 27689441.
  11. Pfeiffer ML, Ozgur OK, Myers JN, Peng A, Ning J, Zafereo ME, Thakar S, Thuro B, Prieto VG, Ross MI, Esmaeli B. Sentinel lymph node biopsy for ocular adnexal melanoma. Acta Ophthalmol. e-Pub 10/2016. PMID: 27775232.
  12. Wang L, Wang X, Li Y, Han S, Zhu J, Wang X, Molkentine DP, Blanchard P, Yang Y, Zhang R, Sahoo N, Gillin M, Zhu XR, Zhang X, Myers JN, Frank SJ. Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. Head Neck. e-Pub 12/2016. PMID: 28039958.
  13. Zhou G, Liu Z, Myers JN. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response. J Cell Biochem 117(12):2682-2692, 12/2016. e-Pub 6/2016. PMID: 27166782.
  14. Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across

Jeffrey N. Myers, M.D., Ph.D., F.A.C.S.

 

 

preneoplastic intermediates. Nat Commun 7:12601, 2016. e-Pub 8/2016. PMCID: PMC5013636.

  1. Hyakusoku H, Sano D, Takahashi H, Hatano T, Isono Y, Shimada S, Ito Y, Myers JN, Oridate N. JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma. J Exp Clin Cancer Res 35(1):6, 2016. e-Pub 1/2016. PMCID: PMC4709939.
  2. Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu N, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. e-Pub 1/2017. PMID: 28126323.
  3. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell 31(2):225-239, 2/2017. PMID: 28196595.
  4. Sandulache VC, Chen Y, Feng L, William WN, Skinner HD, Myers JN, Meyn RE, Li J, Mijiti A, Bankson JA, Fuller CD, Konopleva MY, Lai SY. Metabolic interrogation as a tool to optimize chemotherapeutic regimens. Oncotarget. e-Pub 2/2017. PMID: 28184025.
  5. Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF, Taschner PE, Hainaut P, Soussi T. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res 77(6):1250-1260, 3/2017. PMID: 28254861.
  6. Hatano T, Sano D, Takahashi H, Hyakusoku H, Isono Y, Shimada S, Sawakuma K, Takada K, Oikawa R, Watanabe Y, Yamamoto H, Itoh F, Myers JN, Oridate N. Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines. Int J Cancer 140(7):1571-1580, 4/2017. e-Pub 1/2017. PMID: 28006857.
  7. Quinlan-Davidson SR, Morrison WH, Myers JN, Gunn GB, William WN, Beadle BM, Skinner HD, Gillenwater AM, Frank SJ, Phan J, Johnson FM, Fuller CD, Zafereo ME, Rosenthal DI, Garden AS. Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head Neck 39(4):633-638, 4/2017. e-Pub 12/2016. PMID: 28006086.
  8. Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res. e-Pub 5/2017. PMID: 28476872.
  9. Chang KP, Wang CI, Pickering CR, Huang Y, Tsai CN, Tsang NM, Kao HK, Cheng MH, Myers JN. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. Head Neck 39(6):1131-1137, 6/2017. e-Pub 2/2017. PMID: 28230921.
  10. Schvartsman G, Perez K, Flynn JE, Myers JN, Tawbi H. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. Journal for ImmunoTherapy of Cancer, 6/2017.
  11. Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson FM, Gleber-Netto F, Fu S, Kimmel M, Wang J, Hittelman WN, Pickering CR, Myers JN, Osman AA. Replication stress leading to apoptosis within the S-phase contributes to synergism between vorinostat and AZD1775 in HNSCC harboring high risk TP53 mutation. Clin Cancer Res. e-Pub 8/2017. PMID: 28790110.
  12. Chen TW, Lee CC, Liu H, Wu CS, Pickering CR, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP, Chang YS. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese

 

 

carriers of an APOBEC deletion polymorphism. Nat Commun 8(1):465, 9/2017. e-Pub 9/2017. PMCID: PMC5587710.

  1. Kalu NN, Mazumdar T, Peng S, Shen I, Sambandam V, Rao X, Xi Y, Li L, Qi Y, Gleber-Netto FO, Patel A, Wang J, Frederick MJ, Myers JN, Pickering CR, Johnson FM. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget, 9/2017.
  2. Quinlan-Davidson SR, Mohamed ASR, Myers JN, Gunn GB, Johnson FM, Skinner H, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William WN, Wong AJ, Lai SY, Fuller CD, Morrison WH, Rosenthal DI, Garden AS. Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncol 72:90-97, 9/2017. e-Pub 7/2017. PMID: 28797467.
  3. Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR, Head and Neck Cancer Specialized Program of Research Excellence (SPORE) Human Immunodeficiency Virus (HIV) Supplement Consortium. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer. e-Pub 10/2017. PMID: 29053175.
  4. Faden DL, Thomas S, Cantalupo PG, Agrawal N, Myers J, DeRisi J. Multimodality Analysis Supports APOBEC as a Major Source of Mutations in Head and Neck Squamous Cell Carcinoma. Oral Oncology 74:8-14, 11/2017.
  5. Nader ME, Myers JN, Gidley PW. Sudden hearing loss in a melanoma patient on pembrolizumab: An Etiology not to be omitted in the differential diagnosis. J Immunother Cancer 5:24, 2017. e-Pub 3/2017. PMCID: PMC5359880.
  6. Coaxum SD, Tiedeken J, Garrett-Mayer, E, Myers JN, Rosenzweig SA, Neskey DM. The tumor suppressor capability of p53 is dependent on Non-muscle Myosin IIA function in Head and Neck Cancer. Oncotarget. In Press.